Clinical Trial Update: A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 study evaluating capmatinib in NSCLC patients with MET exon 14 alterations who previously received a MET inhibitor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Malignant Non-small Cell Neoplasm of Lung Stage IV | Phase 2 | Status: COMPLETED | Results posted: 2022-03-14